CORE--TRANSLATIONAL

核心——翻译

• 批准号: 7100740
• 负责人: LYNN Gail DRESSLER
• 金额: $ 13.97万
• 依托单位: UNIV OF NORTH CAROLINA CHAPEL HILL
• 依托单位国家: 美国
• 财政年份: 2004
• 资助国家: 美国
• 起止时间: 2004-12-01 至 2009-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7100740
• 关键词: antibody; biomedical facility; cellular oncology; fluorescent in situ hybridization; gene mutation; histology; histopathology; human genetic material tag; human tissue; immunocytochemistry; immunofluorescence technique; microarray technology; monoclonal antibody; morphology; neoplasm /cancer genetics; pathology

The Translational Core is designed to meet the needs of clinical, basic, and population scientists who require the analysis of human tumors for their research. This need has been made manifest by a large increase in the utilization of tissue sectioning and analysis services by Cancer Center members. Indeed, the ability to gain access to and study human tumor tissue was rated as of "highest priority" for expanded development in the Cancer Center strategic plan. The Core will provide immunohistochemistry (IHC), immunofluorescence (IF), and fluorescence in situ hybridization (FISH) assays for frozen and paraffin embedded tissues, design and histologically confirm tissue micro-arrays from paraffin blocks, characterize and validate monoclonal and polyclonal antibodies for use on tissue sections, and carry out somatic mutational analysis of DNA. The Core will be co-led by Drs. Lynn Dressier, a leader in the use of tissue analysis in translational research, and Leigh Thome, a Pathologist certified in Molecular Pathology. The Core adds value by providing a centralized resource--expertise, quality controlled, assured and validated procedures, state-of-the-art equipment, histopathologic evaluation, and access to human specimens- to perform and interpret morphology-based assays and somatic DNA mutation analysis. Access to and utilization of this core facility will promote the translation of basic science findings to human cancers and allow clinical investigators to perform innovative clinical trials using molecular correlates and endpoints. It will serve population scientists with large numbers of samples requiring morphologic or tissue-based assays. It will also serve as an essential component for molecular epidemiology studies. Future plans include the acquisition of additional equipment for automation and the development of RNA extraction techniques from paraffin blocks.

转化核心旨在满足需要对人类肿瘤进行研究的临床，基础和人群科学家的需求。癌症中心成员利用组织切片和分析服务的利用率很大，这表明了这一需求。实际上，对于癌症中心战略计划的扩大发展，将获得和研究人类肿瘤组织的能力被评为“最高优先级”。核心将提供免疫组织化学（IHC），免疫荧光（IF）和荧光原位杂交（FISH）测定（FISH）测定（FISH），用于冷冻和石蜡嵌入的组织，设计和 组织学上从石蜡块中证实组织微阵列，表征和验证单克隆和多克隆抗体用于组织切片，并对DNA进行体细胞突变分析。核心将由Drs共同领导。 Lynn Dressier，在翻译研究中使用组织分析的领导者，以及通过分子病理学认证的病理学家Leigh Thome。该核心通过提供集中资源（经验丰富，质量控制，保证和经过验证的程序，最新设备，组织病理学）来增加价值 评估并访问人类标本 - 以执行和解释基于形态的测定和体细胞DNA突变分析。该核心设施的获取和利用将促进将基础科学发现转化为人类癌症，并允许临床研究人员使用分子相关和终点进行创新的临床试验。它将为需要大量样本的人群科学家服务，需要形态学或基于组织的测定法。它还将作为分子流行病学研究的重要组成部分。未来 计划包括收购用于自动化的其他设备以及从石蜡块中开发RNA提取技术。